Results 1 to 10 of about 134,006 (246)

Isolated cardiac sarcoidosis: A systematic review [PDF]

Journal of International Medical Research
Background Isolated cardiac sarcoidosis is a distinct entity of sarcoidosis characterized by disease confined exclusively to the heart, without involvement of other organs.
Shokoufeh Hajsadeghi, Elham Piryaie, Shayan Mirshafiee   +2 more
doaj   +2 more sources

Immune mechanisms in fibrotic pulmonary sarcoidosis

European Respiratory Review, 2022
Sarcoidosis is an immune-mediated disorder. Its immunopathology has been steadily mapped out over the past few decades. Despite this, the underpinning mechanisms for progressive fibrotic sarcoidosis is an almost uncharted area.
Praveen Weeratunga, David R. Moller, Ling-Pei Ho   +2 more
doaj   +1 more source

Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes

Diagnostics, 2021
Health-related quality of life (HRQoL), though rarely considered as a primary endpoint in clinical trials, may be the single outcome reflective of patient priorities when living with a health condition.
Lesley Ann Saketkoo, Anne-Marie Russell, Kelly Jensen, Jessica Mandizha, Jinny Tavee, Jacqui Newton, Frank Rivera, Mike Howie, Rodney Reese, Melanie Goodman, Patricia Hart, Bert Strookappe, Jolanda De Vries, Misha Rosenbach, Mary Beth Scholand, Mathew R. Lammi, Marjon Elfferich, Elyse Lower, Robert P. Baughman, Nadera Sweiss, Marc A. Judson, Marjolein Drent   +21 more
doaj   +1 more source

Gender differences in health-related quality of life measured by the Sarcoidosis Health Questionnaire

Scientific Reports, 2021
Sarcoidosis is granulomatous disease, which complex etiology is yet to be fully discovered. In the majority of cases its course is self-limiting. However it can have different clinical manifestations and can be debilitating condition with great impact on
Łukasz Gwadera, Adam J. Białas, Witold Górski, Mikołaj A. Iwański, Joanna Miłkowska-Dymanowska, Paweł Górski, Wojciech J. Piotrowski   +6 more
doaj   +1 more source

The Role of Echocardiography in the Contemporary Diagnosis and Prognosis of Cardiac Sarcoidosis: A Comprehensive Review

Life, 2023
Cardiac sarcoidosis (CS) is a rare inflammatory disorder characterised by the presence of non-caseating granulomas within the myocardium. Contemporary studies have revealed that 25–30% of patients with systemic sarcoidosis have cardiac involvement, with ...
Joseph Okafor, Rajdeep Khattar, Rakesh Sharma, Vasilis Kouranos   +3 more
doaj   +1 more source

Sarcoidosis Illuminations on Living During COVID-19: Patient Experiences of Diagnosis, Management, and Survival Before and During the Pandemic

Journal of Patient Experience, 2022
Background: Inspired by intense challenges encountered by patients and clinicians, we examined the experiences of living with sarcoidosis in three of the hardest impacted English-speaking cities during the early COVID-19 pandemic: London, New Orleans ...
Lesley Ann Saketkoo MD, MPH, Kelly Jensen MD, MPH, Dimitra Nikoletou PhD, MSc, Jacqui J. Newton, Frank J. Rivera BA, Mike Howie, Rodney K. Reese, Melanie Goodman BS, Patricia B. Hart MBA, Whitney Bembry MD, Adam Russell BA, Isabelle Lian MS, Matthew R. Lammi MD, MSCR, Mary Beth Scholand MD, Anne-Marie Russell PhD, APRN, ATSF   +14 more
doaj   +1 more source

Sarcoidosis lung transplantation waitlist mortality, a national registry database study

ERJ Open Research, 2023
Background The Lung Allocation Score (LAS) prioritises lung transplantation candidates, balancing waitlist mortality and post-transplant survival. The score groups sarcoidosis candidates based on mean pulmonary artery pressure: those with ≤30 mmHg ...
Derlis C. Fleitas Sosa, Shameek Gayen, Matthew Zheng, Andrew J. Gangemi, Huaqing Zhao, Victor Kim, Sameep Sehgal, Gerard J. Criner, Rohit Gupta, A. James Mamary   +9 more
doaj   +1 more source

Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study

Respiratory Research, 2022
Background Pirfenidone slows down disease progression in idiopathic pulmonary fibrosis (IPF). Recent studies suggest a treatment effect in progressive pulmonary fibrosis other than IPF.
Jelle R. Miedema, Catharina C. Moor, Marcel Veltkamp, Sara Baart, Natascha S. L. Lie, Jan C. Grutters, Marlies S. Wijsenbeek, Rémy L. M. Mostard   +7 more
doaj   +1 more source

The Relationship between Tumor Development and Sarcoidosis in Aspects of Carcinogenesis before and after the Onset of Sarcoidosis

Medicina, 2022
Background and Objectives: It is still unclear whether sarcoidosis is likely to be associated with tumors. In addition, the use of an immune checkpoint inhibitor has been reported to initiate the onset of sarcoidosis.
Yoshimasa Hachisu, Yasuhiko Koga, Shu Kasama, Kyoichi Kaira, Shogo Uno, Masakiyo Yatomi, Haruka Aoki-Saito, Hiroaki Tsurumaki, Asuka Jingu, Noriaki Sunaga, Toshitaka Maeno, Takeshi Hisada   +11 more
doaj   +1 more source

Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study

BMC Pulmonary Medicine, 2020
Background Treatment of pulmonary sarcoidosis is recommended in case of significant symptoms, impaired or deteriorating lung function. Evidence-based treatment recommendations are limited and largely based on expert opinion.
Vivienne Kahlmann, Montse Janssen Bonás, Catharina C. Moor, Coline H. M. van Moorsel, Mirjam Kool, Raisa Kraaijvanger, Jan C. Grutters, Mayka Overgaauw, Marcel Veltkamp, Marlies S. Wijsenbeek, Collaborating investigators   +10 more
doaj   +1 more source